CCL17 levels as a biomarker for the high-risk variant of T-LBL – Princess Máxima Center for Pediatric Oncology

Princess Máxima Center for Pediatric Oncology shared on LinkedIn:

“Researchers from the Máxima Center have found the most common cause of recurrent T-cell lymphoblastic lymphoma (T-LBL). These NOTCH1 gene fusions are linked to increased CCL17 levels in the blood. As a result, CCL17 levels can be used as a biomarker for the high-risk variant of T-LBL. The discovery of the gene fusions and biomarker brings personalized treatment of children with this variant of T-LBL one step closer.

PhD student Emma Kroeze and bioinformatician Michelle Kleisman analyzed the data of 29 children with T-LBL treated at Máxima between 2018 and 2023. ‘This study clearly shows how important data comparisons are to make progress within pediatric oncology research.’

The next step is to work with pediatric oncologists from across Europe to determine the most appropriate treatment for this high-risk group of children. In addition, a larger group of children will be studied in European studies.”

Read further.
Source: Princess Máxima Center for Pediatric Oncology/LinkedIn

.